Oral products dominate CGRP inhibitor sales, as several drugs rise

As two oral CGRP inhibitors, AbbVie’s Ubrelvy and Pfizer’s Nurtec, continue to vie for the class’ top quarterly migraine sales, AbbVie’s newer oral therapy, Qulipta, is ascending the ranks. In recent quarters, Qulipta sales have surpassed those of two subcutaneous therapies and one intravenous product to rise to the middle of the seven-member pack.  

In 3Q23, sales of Ubrelvy ubrogepant from AbbVie Inc. (NYSE:ABBV) matched those of Nurtec rimegepant from Pfizer Inc. (NYSE:PFE) at $233 million apiece. Despite fluctuation from quarter-to-quarter, both therapies have generally been on an upward trajectory, raising the question of whether one or both could reach blockbuster status next year...